디에이치엑스컴퍼니

031860KOSDAQ상품 종합 도매업

51.5 / 100

Reference Date: 2026-04-13

Financial Score18.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure11.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 30.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DHX Company operates diverse businesses including bicycle manufacturing, ICT distribution, biomedicine development, and regional specialty product exports, with the ICT division contributing over 90% of sales. Key products include the blood purification device 'Hemapure', AI-based brain diagnostic tool 'Neuroharmony', and immunopain treatment drug 'Afitoxin', while also conducting R&D in biocosmetics based on skin microbiome technology.

Number of Employees

27people

Average Salary

5.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 8.144.0Point

PBR

0.28Industry Average 0.515.5Point

Lower than industry avg (good)

ROE

-34.15Industry Average 5.310.0Point

Well below industry avg

Debt Ratio

18.86Industry Average 38.056.5Point

Half of industry avg (excellent)

Trend 2022~20242.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼24.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -44.3% (improving, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 693Won52-week high 1,70952-week low 265

1-month return6.0Point

1m +30.51% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

21 totalPositive 2Neutral 18Negative 1

Neutral[기재정정]주요사항보고서(유형자산양수결정)2026-04-10
Neutral조회공시요구(현저한시황변동)에대한답변(미확정)2026-04-10
Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-04-09
Neutral대표이사변경2026-04-09
Neutral[기재정정]최대주주변경2026-04-08